Adult Glioblastoma, Bevacizimab, Magnetic Resonance Imaging
Conditions
Keywords
Recurrent Glioblastoma; Bevacizumab; Imaging
Brief summary
This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.
Detailed description
Although overall the effects on prolonging survival in bevacizumab-treated patients is modest at best, it is still unclear whether there is not a more substantial positive effect in a subset of patients, potentially identifiable by imaging markers. Allowing for prediction of good or bad responder from anti-angiogenic therapy prior to treatment completion is important to select patients most likely to benefit from anti-angiogenic treatment. This is a prospective observational study and no active comparator will be used. Study participants include adult patients with recurrent glioblastoma. We hypothesized that quantifying changes in multi-modal advanced MR imaging techniques would allow early treatment response and long-term prediction in glioblastomas.
Interventions
DIAGNOSTIC_TEST3-Tesla conventional magnetic resonance imaging
T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
DIAGNOSTIC_TESTAdvanced imaging without contrast use
Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
DIAGNOSTIC_TESTDynamic susceptibility contrast-weighted imaging
Cerebral blood volume and vessel architectural imaging parameters
Sponsors
Ho Sung Kim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients had histologically confirmed glioblastoma with progression diagnosed on the basis of clinical data and MRI after standard treatment of operation, concurrent chemoradiotherapy, and adjuvant temozolomide; 2. Patients were more than 3 months from chemoradiotherapy to avoid the confounding factor of radiation necrosis (pseudoprogression); 3. Ability to understand and the willingness to sign a written informed consent document; all patients, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines
Exclusion criteria
1. Patients were not subject to therapies other than anti-angiogenic treatment, including re-operation, re-irradiation, or immunotherapies, because of the patient's clinical status and indication 2. Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc), because such devices may be displaced or malfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Average 9 months | Time from anti-angiogenic treatment until death or the first imaging report indicating worsening/progression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-month progression | 6 month | Pathologic confirmation following second look surgery or clinico-radiological assessment at 6-month |
| Overall survival | Average 12 months | Time from anti-angiogenic treatment to death |
Countries
South Korea
Outcome results
None listed